Federal judges in Delaware and Indiana will hear arguments today in drug manufacturers’ AstraZeneca and Eli Lilly’s separate lawsuits challenging the 340B contract pharmacy requirements.
A judge in Wilmington, Del., earlier this week denied AstraZeneca’s motion for an emergency stay in its suit against the U.S. Health and Human Services Department. The request was prompted by the U.S. Health Resources and Services Administration’s May 17 letters to Astra and five other manufacturers informing them that their denial of and conditions on 340B pricing on drugs dispensed by contract pharmacies are illegal and must end immediately. HRSA asked the companies by June 1 to share their plans to resume contract pharmacy-related sales. It said it will decide whether civil monetary penalties against the companies are warranted based on each company’s “willingness to comply with its obligations” under the 340B statute.
Federal judges in Delaware and Indiana will hear arguments today in drug manufacturers’ AstraZeneca and Eli Lilly’s separate lawsuits challenging the 340B contract pharmacy requirements.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.